India's COVID-19 caseload crosses 88 lakh-mark with 41,100 new cases; toll reaches 1,29,635

-

New Delhi: India's COVID-19 caseload has gone past the 88-lakh mark, while the number of people who have recuperated from the disease has crossed 82 lakh, pushing the national recovery rate to 93.09 percent, according to the health ministry's data updated on Sunday.

The total number of coronavirus cases mounted to 88,14,579 with 41,100 of those reported in a day, while the death toll climbed to 1,29,635 with 447 new fatalities, the data updated at 8 am showed.

The number of active cases remained below five lakh for the fifth consecutive day. There are 4,79,216 active cases of the coronavirus infection in the country as on date, which accounts for 5.44 percent of the total caseload, the data stated.

The total number of recoveries has surged to 82,05,728, pushing the national recovery rate to 93.09 percent, while the COVID-19 case fatality rate stands at 1.47 percent.

The country's COVID-19 tally had crossed the 20-lakh mark on 7 August, 30 lakh on 23 August and 40 lakh on 5 September.

It went past the 50-lakh mark on 16 September, 60 lakh on 28 September, 70 lakh on 11 October and 80 lakh on 29 October.

According to the Indian Council of Medical Research (ICMR), a total of 12,48,36,819 samples were tested for COVID-19 up to 14 November with 8,05,589 of those tested on Saturday.

The 447 new fatalities include 105 from Maharashtra, 96 from Delhi, 53 from West Bengal, 27 from Uttar Pradesh and 26 from Kerala.

A total of 1,29,635 deaths have so far been reported in the country due to the disease, with Maharashtra accounting for the highest number of 45,914, followed by Karnataka (11,508), Tamil Nadu (11,466), West Bengal (7,610), Delhi (7,519), Uttar Pradesh (7,354), Andhra Pradesh (6,854), Punjab (4,428) and Gujarat (3,797).

The ministry stressed that more than 70 per cent of the deaths occurred due to comorbidities.

"Our figures are being reconciled with the Indian Council of Medical Research," the ministry said on its website, adding that a state-wise distribution of the figures is subject to further verification and reconciliation.



from Firstpost India Latest News https://ift.tt/3noEh3V
Press Trust of India

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more